Literature DB >> 18304211

Alpha1-adrenoceptor subtypes and lower urinary tract symptoms.

Debra A Schwinn1, Claus G Roehrborn.   

Abstract

Benign prostatic hyperplasia (BPH) is a common cause of urinary outflow obstruction in aging men leading to lower urinary tract symptoms (LUTS). alpha(1)-Adrenoceptors (alpha(1)ARs) antagonists (blockers) have become a mainstay of LUTS treatment because they relax prostate smooth muscle and decrease urethral resistance, as well as relieving bladder LUTS symptoms. A review of key recent clinical trials suggests new insights into the role of specific alpha(1)AR subtypes in the treatment of LUTS.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18304211      PMCID： PMC2329815          DOI： 10.1111/j.1442-2042.2007.01956.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN： 0919-8172            Impact factor:   3.369


  57 in total

Review 1.  Subtypes of functional alpha1- and alpha2-adrenoceptors.

Authors:  J R Docherty
Journal:  Eur J Pharmacol       Date:  1998-11-13       Impact factor: 4.432

2.  Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group.

Authors:  H Lepor
Journal:  Urology       Date:  1998-06       Impact factor: 2.649

3.  Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha 1-adrenergic receptor subtypes.

Authors:  C D Richardson; C F Donatucci; S O Page; K H Wilson; D A Schwinn
Journal:  Prostate       Date:  1997-09-15       Impact factor: 4.104

Review 4.  International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update.

Authors:  J P Hieble; D B Bylund; D E Clarke; D C Eikenburg; S Z Langer; R J Lefkowitz; K P Minneman; R R Ruffolo
Journal:  Pharmacol Rev       Date:  1995-06       Impact factor: 25.468

Review 5.  Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact on safety and well-being.

Authors:  C de Mey
Journal:  Eur Urol       Date:  1998       Impact factor: 20.096

6.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

Authors:  J D McConnell; R Bruskewitz; P Walsh; G Andriole; M Lieber; H L Holtgrewe; P Albertsen; C G Roehrborn; J C Nickel; D Z Wang; A M Taylor; J Waldstreicher
Journal:  N Engl J Med       Date:  1998-02-26       Impact factor: 91.245

7.  Alpha1-adrenergic receptor subtypes in human detrusor.

Authors:  B J Malloy; D T Price; R R Price; A M Bienstock; M K Dole; B L Funk; X L Rudner; C D Richardson; C F Donatucci; D A Schwinn
Journal:  J Urol       Date:  1998-09       Impact factor: 7.450

8.  Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review.

Authors:  T J Wilt; A Ishani; G Stark; R MacDonald; J Lau; C Mulrow
Journal:  JAMA       Date:  1998-11-11       Impact factor: 56.272

9.  Micturition in conscious rats with and without bladder outlet obstruction: role of spinal alpha 1-adrenoceptors.

Authors:  O Ishizuka; K Persson; A Mattiasson; A Naylor; M Wyllie; K Andersson
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

10.  A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing.

Authors:  C de Mey; M C Michel; J McEwen; T Moreland
Journal:  Eur Urol       Date:  1998       Impact factor: 20.096
View more
  57 in total

1.  Pathophysiology of benign prostatic hyperplasia: insights from medical therapy for the disease.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2009

2.  Efficacy of alpha-Adrenergic Receptor Blockers in the Treatment of Male Lower Urinary Tract Symptoms.

Authors:  Claus G Roehrborn
Journal:  Rev Urol       Date:  2009

3.  Medical treatment of benign prostatic hyperplasia.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2011

4.  α1-adrenergic receptor antagonists versus placebo for female lower urinary tract symptoms: A meta-analysis.

Authors:  Peng Zhang; Wan-Li Hu; Bei Cheng; Long Cheng; Xiao-Kan Xiong
Journal:  Exp Ther Med       Date:  2015-04-23       Impact factor: 2.447

Review 5.  [Acute urinary retention in men: efficacy of alpha-blockers in catheter removal after urinary retention].

Authors:  S Mühlstädt; M Oelke
Journal:  Urologe A       Date:  2019-06       Impact factor: 0.639

6.  Inhibition of adrenergic human prostate smooth muscle contraction by the inhibitors of c-Jun N-terminal kinase, SP600125 and BI-78D3.

Authors:  F Strittmatter; S Walther; C Gratzke; J Göttinger; C Beckmann; A Roosen; B Schlenker; P Hedlund; K E Andersson; C G Stief; M Hennenberg
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 7.  Silodosin is effective for treatment of LUTS in men with BPH: a systematic review.

Authors:  Hui Ding; Wan Du; Zi-Zhen Hou; Han-Zhang Wang; Zhi-Ping Wang
Journal:  Asian J Androl       Date:  2012-12-10       Impact factor: 3.285

8.  α-Blockers for the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome: An Update on Current Clinical Evidence.

Authors:  J Curtis Nickel; Naji Touma
Journal:  Rev Urol       Date:  2012

Review 9.  Silodosin in the treatment of benign prostatic hyperplasia.

Authors:  Maxime Rossi; Thierry Roumeguère
Journal:  Drug Des Devel Ther       Date:  2010-10-27       Impact factor: 4.162

Review 10.  Intraoperative floppy iris syndrome: an updated review of literature.

Authors:  Amit Kumar; Amit Raj
Journal:  Int Ophthalmol       Date:  2021-06-29       Impact factor: 2.031
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.